IBRX
NASDAQ HealthcareImmunityBio, Inc. - Common Stock
Biotechnology
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
�� 市场数据
| 价格 | $7.70 |
|---|---|
| 成交量 | 20,940,341 |
| 市值 | 7.95B |
| 贝塔系数 | 0.060 |
| RSI（14日） | 53.1 |
| 200日均线 | $4.06 |
| 50日均线 | $7.97 |
| 52周最高 | $12.43 |
| 52周最低 | $1.83 |
| Forward P/E | -385.00 |
| Price / Book | -15.56 |
🎯 投资策略评分
IBRX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (69/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🎈 Over-Hyped (14/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 IBRX in your text
粘贴任何文章、记录或帖子 — 工具将提取 IBRX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.